CorMedix (CRMD) vs Ovid Therapeutics (OVID)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Ovid Therapeutics (OVID) has outperformed CorMedix (CRMD) over the past year, gaining 57.1% versus a loss of 45.6%. Over five years, CRMD leads with a +3.9% price change compared with -32.5% for OVID. CorMedix is the larger company by market cap ($419.2 million vs $415.2 million), about 1.0 times the size, while Ovid Therapeutics is growing revenue faster (+1181.3% vs +617.0%).
CorMedix converts more of its revenue into profit, with a net margin of 52.3% versus -240.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRMD | OVID |
|---|---|---|
| Share price | $5.27 | $2.20 |
| Market cap | $419.16M | $415.21M |
| 1-day change | +3.74% | -5.98% |
| YTD return | -54.69% | +34.97% |
| 1-year return | -45.56% | +57.14% |
| 5-year return | +3.94% | -32.52% |
| P/E ratio (TTM) | 8.23 | — |
| Forward P/E | 15.06 | — |
| EPS (TTM) | $0.64 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $311.71M | $7.25M |
| Revenue growth (YoY) | +617.03% | +1181.27% |
| Net income (latest FY) | $163.06M | $-17.41M |
| Gross margin | 88.46% | — |
| Operating margin | 48.17% | -585.20% |
| Net margin | 52.31% | -240.13% |
| 52-week high | $13.02 | $3.11 |
| 52-week low | $4.47 | $1.26 |
| Distance from 52-week high | -59.52% | -29.15% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +161.86% | +179.55% |
| Average volume | 1.44M | 1.98M |
| Shares outstanding | 79.54M | 188.73M |
| Employees | 191 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OVID has outperformed CRMD by 102.7 percentage points over the past year.
- CorMedix is more profitable, keeping 52.3 cents of every revenue dollar as net income versus -240.1 cents for Ovid Therapeutics.
- Ovid Therapeutics grew revenue faster in its latest fiscal year (+1181.27% vs +617.03%).
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Health Care · Biotechnology: Pharmaceutical Preparations · 191 employees
About Ovid Therapeutics
OVID stock →Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
CRMD vs OVID FAQ
Which is bigger, CorMedix or Ovid Therapeutics?
CorMedix (CRMD) is larger, with a market capitalization of $419.16M compared with $415.21M for Ovid Therapeutics (OVID).
Which stock has performed better over the past year, CRMD or OVID?
OVID returned +57.14% over the past 12 months, compared with -45.56% for CRMD (price return, excluding dividends). Past performance does not predict future results.
Are CorMedix and Ovid Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.